Robert N Taub

US Patent:

20120311445, Dec 6, 2012

Filed:

Jun 5, 2012

Appl. No.:

13/489393

Inventors:

J. Alexander Cabanilla - New York NY, US
Jonathan Sheldrick - New York NY, US
Robert Taub - Princeton NJ, US

Assignee:

MuseAmi, Inc. - Princeton NJ

International Classification:

G06F 3/01

US Classification:

715716

Abstract:

Enhanced features are provided by enhanced feature data stored with an enhanced media file in a conventional media container format. The enhanced feature data is not recognized by a conventional playback application, which produces the conventional playback experience of the media file for a user who lacks a suitably configured enhanced media file application. The enhanced feature data is recognized by a suitably configured enhanced media file application, which processes the enhanced feature data and responds to user inputs to support the enhanced user features and interaction in conjunction with playback of the enhanced media file.

US Patent:

20210402014, Dec 30, 2021

Filed:

Sep 14, 2021

Appl. No.:

17/474916

Inventors:

Robert Norman TAUB - New York NY, US

International Classification:

A61K 51/04
A61P 35/00
A61K 51/02

Abstract:

The invention provides a compound having the following structure:wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran—dodecane tetraacetic acid—radioactive isotope compound in a pharmaceutically effective vehicle.

US Patent:

20210290786, Sep 23, 2021

Filed:

Mar 22, 2021

Appl. No.:

17/208970

Inventors:

Robert Norman TAUB - New York NY, US

International Classification:

A61K 51/06
A61K 51/04
A61K 51/12

Abstract:

The invention provides a compound having the following structure:wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.

US Patent:

20210283280, Sep 16, 2021

Filed:

Mar 11, 2020

Appl. No.:

16/815759

Inventors:

Robert Norman TAUB - New York NY, US

International Classification:

A61K 51/04
A61K 51/02
A61P 35/00

Abstract:

The invention provides a compound having the following structure:wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran-dodecane tetraacetic acid-radioactive isotope compound in a pharmaceutically effective vehicle.

US Patent:

20180185321, Jul 5, 2018

Filed:

Jun 27, 2016

Appl. No.:

15/740938

Inventors:

- New York NY, US
Robert Norman Taub - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 31/337
A61K 31/407
A61K 31/704
A61K 31/7068
A61K 33/24
A61K 38/14
A61K 47/02
A61K 47/68
A61P 35/00
A61K 9/00

Abstract:

Provided herein are compositions and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a therapeutic agent and a substrate. Another aspect provides methods for treating a disease, disorder, or condition.

US Patent:

20160331853, Nov 17, 2016

Filed:

Jan 21, 2015

Appl. No.:

15/112589

Inventors:

- New York NY, US
Robert N. Taub - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 51/04
A61K 47/02
A61K 47/26
A61K 47/10
A61K 47/24
A61K 47/22
A61K 47/18
A61K 51/08

Abstract:

Provided herein are compositions and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a kit including a first composition including a bare ligand or a ligand coupled to a molecule or substrate; and a second composition including a receptor coupled to a radioisotope. Another aspect provides methods for treating a disease, disorder, or condition.

US Patent:

20160012853, Jan 14, 2016

Filed:

Jul 8, 2015

Appl. No.:

14/794743

Inventors:

- Princeton NJ, US
Courtenay Cotton - New York NY, US
Brendan Elliott - Hopewell NJ, US
Ariel Melendez - Hillsborough NJ, US
Jon Sheldrick - Brooklyn NY, US
Robert D. Taub - Princeton NJ, US
Michael Westendorf - East Windsor NJ, US

International Classification:

G11B 27/036
H04L 29/08
H04N 9/802
G11B 27/30
G11B 20/10
H04L 29/06
G11B 27/34

Abstract:

A user performance that can include audio and video performance may be added to a multi-track clip. The combined user performance and clip can be stored at a local device as a composite performance, and effects processing may be applied to the user performance. The composite performance may be previewed and can be sent to a computer device over a computer network for sharing with other users.